In this article, Pharmaguy presents the best images from Pharma Marketing Blog, which cover topics of importance in 2014: DTC and drug promotion spending, drug risks and adverse events, drug industry reputation, FDA and social media regulatory guidelines, mobile apps, and drug development costs.
Welcome to Vol. 14, Issue No. 6 (SEPTEMBER 2015) of Pharma Marketing News. Medical conference hashtags, celebrities + social media, and Patient Power are the themes of this issue.
The FDA approved a total of 41 new molecular entities (NMEs) and biologics (BLAs) in 201 4but sent out only a meager 10 advertising enforcement letters in 2014, the fewest ever.
With the renewed focus on the high cost of drugs comes a new wave of attacks on Direct-to-Consumer Advertising (DTCA) of prescription drugs. But is there a causal link between DTC advertising and Rx drug prices and/or total spending? This article explores this issue.
This article presents a case study of how patient input has the power to change the course of drug approval. The case is Sprout's ground-breaking patient campaign that played a major role in getting Addyi, a female sexual dysfunction drug, approved by the FDA.
Welcome to Volume 14, Issue #1 (JANUARY 2015) of Pharma Marketing News.
Welcome to Vol. 14, Issue No. 7 (DECEMBER 2015) of Pharma Marketing News. DTC Ban Revisited, Digital Disruption, Best of 2015, are the themes of this issue.
Welcome to Vol. 14, Issue No. 5 (JUNE 2015) of Pharma Marketing News. Creativity and new technology in the service of patient communications and healthcare outcomes are the themes of this issue.
Welcome to Vol. 14, Issue No. 2 (FEBRUARY 2015) of Pharma Marketing News. The FDA is a hot topic in this issue. Specifically, it's new thinking on presenting risk information in direct-to-consumer print ads. Are the new guidelines relevant for online advertising?
This article summarizes the results of the KOL Name Change Survey and discusses how to change the underlying process by which pharma companies choose KOLs.